CEO, Deciduous Therapeutics
Robin Mansukhani is the CEO and Co-Founder of Deciduous Therapeutics, a venture-backed start-up developing novel immunotherapies to treat age related diseases. He also been an advisor to several early stage biotech companies in the Aging and CNS space including Therini Bio and Reservoir Neurosciences. Previously, Robin co-founded and served as President and CEO of Alzeca Biosciences, a diagnostic imaging company for CNS disorders, which is supported by venture investors, the Alzheimer's Drug Discovery Foundation, and an NIH Direct to Phase 2 Grant.
Robin has been an invited keynote speaker both domestically and abroad, including TEDx. Previously, Mr. Mansukhani worked in early stage venture capital at The Maple Fund and investment banking at Axiom Capital. He has also co-founded BlueStamp Engineering, an intensive, project-based engineering program for high school students. Robin previously served a term in AmeriCorps where he led health and literacy programs. Mr. Mansukhani holds a B.S. in Biochemistry from Case Western Reserve University.